Methotrexate & Rheumatoid Arthritis Associated Atherosclerosis: A Narrative Review of Multidisciplinary Approach for Risk Modification by the International Board of Experts Publisher Pubmed



Avagimyan A¹ ; Fogacci F² ; Pogosova N³ ; Kakturskiy L⁴ ; Jndoyan Z⁵ ; Faggiano A^{6, 7} ; Bairamyan T⁸ ; Agati L⁹ ; Sattar Y¹⁰ ; Mkrchyan L¹¹ ; Avetisyan G²⁹ ; Ginosyan K¹² ; Aznauryan A¹³ ; Sahakyan K¹⁴ Show All Authors
Source: Current Problems in Cardiology Published:2024

Abstract

Rheumatoid arthritis (RA) is an idiopathic, autoimmune connective tissue disorder that primarily affects the synovial joints, causing symmetric, erosive-deforming polyarthritis. It is also associated with extra-articular manifestations, particularly cardiovascular (CV) diseases (CVD). CV risk modification in RA remains unsolved despite recent advances in the management of RA. RA is an independent risk factor for atherosclerosis. RA and atherosclerosis share similar pathophysiological features (such as the pro-inflammatory cascade activation including interleukin-6) and risk factors (such as microflora dysbacteriosis and smoking). Patients with RA experience an exacerbation of atherogenesis, with atheromas destabilization, endothelial dysfunction, vasculitis, and hypercytokinemia. Consequently, the inflammatory response associated with RA is the basis for CVD development. The treat-to-target strategy not only improved RA control but also had a favorable effect on the morpho-functional state of the CV system in patients living with RA. Thus, disease-modifying antirheumatic drugs (DMARDs) – in particular methotrexate – may have a beneficial effect on the prevention of CV events in RA. It must be mentioned that RA is a serious multi-system disease, not only because of a window period during which the course of RA can be reversed, but also due to early damage to the heart and blood vessels. For this reason, a thorough cardiological assessment must be performed for all patients with RA, regardless of sex, age, disease stage, and disease activity score. © 2023 Elsevier Inc.